Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
US-9522123-B2 · Dec 20, 2016 · US
Use of cannabinoids in the treatment of epilepsy
US10137095B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10137095-B2 |
| Application number | US-201715449535-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 3, 2017 |
| Priority date | Oct 14, 2014 |
| Publication date | Nov 27, 2018 |
| Grant date | Nov 27, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of reducing drop seizure frequency in a patient with Lennox-Gastaut syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) Δ9-tetrahydrocannabinol (THC); and wherein the dose of the CBD is about 20 mg/kg/day. 2. The method of claim 1 , wherein the CBD is administered in combination with one or more concomitant anti-epileptic drugs (AED) to the subject in need thereof at a recommended therapeutic dose of the AED. 3. The method of claim 1 , wherein the one or more AED is selected from the group consisting of: clobazam; clonazepam, levetiracetam; topiramate; stiripentol; phenobarbital; lacsamide; valproic acid; zonisamide; perampanel; and fosphenytoin. 4. A method of reducing drop seizure frequency in a patient with Lennox-Gastaut syndrome, comprising administering to the patient in need thereof cannabidiol (CBD) and clobazam, wherein the CBD has a purity of at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) Δ9-tetrahydrocannabinol (THC); and wherein the dose of the CBD is about 20 mg/kg/day. 5. A method of treating drop seizures in a patient with Lennox-Gastaut syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) Δ9-tetrahydrocannabinol (THC); and wherein the dose of the CBD is about 20 mg/kg/day. 6. The method of claim 5 , wherein the CBD is administered in combination with one or more concomitant anti-epileptic drugs (AED) to the subject in need thereof at a recommended therapeutic dose of the AED. 7. The method of claim 5 , wherein the one or more AED is selected from the group consisting of: clobazam; clonazepam, levetiracetam; topiramate; stiripentol; phenobarbital; lacsamide; valproic acid; zonisamide; perampanel; and fosphenytoin. 8. A method of treating drop seizures in a patient with Lennox-Gastaut syndrome, comprising administering to the patient in need thereof cannabidiol (CBD) and clobazam, wherein the CBD has a purity of at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) Δ9-tetrahydrocannabinol (THC); and wherein the dose of the CBD is about 20 mg/kg/day.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antiepileptics; Anticonvulsants · CPC title
Drugs for disorders of the nervous system · CPC title
Solutions {(composition of solutions A61K47/00)} · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10137095B2 cover?
- The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The …
- Who is the assignee on this patent?
- Gw Pharma Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/05. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).